VIKTORIA-1
14 Sep 2023
VIKTORIA-1
NCT05501886
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Celcuity, Inc.
Cancer Type | Breast Cancer |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2022-09-30 |
Anticipated End Date | 2026-09-30 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
Pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Amanda Townsend |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs